103 related articles for article (PubMed ID: 2307842)
1. Purification of 1F5 antigen that prevents complement attack on homologous cell membranes.
Harada R; Okada N; Fujita T; Okada H
J Immunol; 1990 Mar; 144(5):1823-8. PubMed ID: 2307842
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.
Okada N; Harada R; Fujita T; Okada H
J Immunol; 1989 Oct; 143(7):2262-6. PubMed ID: 2476502
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody that blocks the complement regulatory activity of guinea pig erythrocytes and characterization of the antigen involved as guinea pig decay-accelerating factor.
Okada N; Tanaka H; Takizawa H; Okada H
J Immunol; 1995 Jun; 154(11):6103-11. PubMed ID: 7538542
[TBL] [Abstract][Full Text] [Related]
4. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
5. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
6. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
Davé SJ; Sodetz JM
J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
[TBL] [Abstract][Full Text] [Related]
7. Homologous species restriction in lysis of erythrocytes by terminal complement proteins.
Hänsch GM; Hammer CH; Vanguri P; Shin ML
Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5118-21. PubMed ID: 6946459
[TBL] [Abstract][Full Text] [Related]
8. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
Schönermark S; Rauterberg EW; Shin ML; Löke S; Roelcke D; Hänsch GM
J Immunol; 1986 Mar; 136(5):1772-6. PubMed ID: 2419413
[TBL] [Abstract][Full Text] [Related]
9. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
Kitamura H; Tsuboi M
Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
[TBL] [Abstract][Full Text] [Related]
11. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
Deng J; Gold D; LoVerde PT; Fishelson Z
Int J Parasitol; 2007 Jan; 37(1):67-75. PubMed ID: 17123534
[TBL] [Abstract][Full Text] [Related]
12. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.
Okada H; Tanaka H; Okada N
Eur J Immunol; 1983 Apr; 13(4):340-4. PubMed ID: 6221932
[TBL] [Abstract][Full Text] [Related]
13. Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9.
Boyle MD; Gee AP; Okada M; Borsos T
J Immunol; 1980 Dec; 125(6):2818-22. PubMed ID: 7430645
[TBL] [Abstract][Full Text] [Related]
14. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
[TBL] [Abstract][Full Text] [Related]
15. Evasion of the alternative complement pathway by metacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate.
Sher A; Hieny S; Joiner K
J Immunol; 1986 Nov; 137(9):2961-7. PubMed ID: 3531342
[TBL] [Abstract][Full Text] [Related]
16. On the cause and nature of C9-related heterogeneity of terminal complement complexes generated on target erythrocytes through the action of whole serum.
Bhakdi S; Tranum-Jensen J
J Immunol; 1984 Sep; 133(3):1453-63. PubMed ID: 6747293
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain.
Brannen CL; Sodetz JM
Mol Immunol; 2007 Feb; 44(5):960-5. PubMed ID: 16624411
[TBL] [Abstract][Full Text] [Related]
18. Functional properties of the asialo-fifth component of human complement.
Schultz DR; Arnold PI
J Immunol; 1990 Jul; 145(2):655-61. PubMed ID: 2114446
[TBL] [Abstract][Full Text] [Related]
19. The C8-binding protein of human erythrocytes: interaction with the components of the complement-attack phase.
Schönermark S; Filsinger S; Berger B; Hänsch GM
Immunology; 1988 Apr; 63(4):585-90. PubMed ID: 3366469
[TBL] [Abstract][Full Text] [Related]
20. T-cell-activating monoclonal antibodies, reacting with both leukocytes and erythrocytes, recognize the guinea pig Thy-1 differentiation antigen: characterization and cloning of guinea pig CD90.
Schäfer H; Bartels T; Hahn G; Otto A; Burger R
Cell Immunol; 1999 Nov; 197(2):116-28. PubMed ID: 10607429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
